BIAF

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung Presentation to address current challenges in pulmonary nodule management and to discuss preliminary research data from the ongoing development of a new, investigational test for asthma and COPD bioAffinity Technologies' Medical and Scientific Advisory Board to convene in conjunction with CHEST 2026 bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, will sponsor a Learning Theater presentation at CHEST 2026, the annual meeting of the American College of

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

PRER14A - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

JERSEY CITY, N.J., Oct. 9, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, has closed its previously announced registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) with an institutional investor at a purchase price of $6.122 (or $6.115 per pre-funded warrant), in a registered direct offering priced at-the-market under Nasdaq rules.Additionally, the Company closed its previously announced co

424B5 - bioAffinity Technologies, Inc. (0001712762) (Filer)

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has closed its previously announced registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) with an institutional investor at a purchase price of $6.122 (or $6.115 per pre-funded warrant), in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, the Company closed its previously announced concurrent private placement of warrants to purchase up to an aggregate 980,072 shares of common stock at an exercise price of $6.122 per

424B5 - bioAffinity Technologies, Inc. (0001712762) (Filer)

JERSEY CITY, N.J., Oct. 8, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, has entered into a definitive agreement with an institutional investor to sell shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $6.122 (or $6.115 per pre-funded warrant), in a registered direct offering priced at-the-market under Nasdaq rules.Additionally in a concurrent private placement the Company will sell warrants

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has entered into a definitive agreement with an institutional investor to sell shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $6.122 (or $6.115 per pre-funded warrant), in a registered direct offering priced at-the-market under Nasdaq rules. Additionally in a concurrent private placement the Company will sell warrants to purchase up to an aggregate 980,072 shares of common stock at an exercise price of $6.122 per share. The pre-funded warrants will hav

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Company’s expanding intellectual property portfolio strengthens protection for its early lung cancer diagnostic in Asia Patent strategy protects proprietary CyPath Lung flow cytometry+AI approach in international markets bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Japan Patent Office has issued a Notice of Allowance indicating its intention to grant a patent to bioAffinity Technologies for the method of predicting the likelihood of lung cancer powered by the CyPath® Lung test for early-stage lung cancer. The Japanese

Nearly 90% increase in number of physician offices using CyPath Lung Utilization expands as physicians who ordered CyPath Lung in 2025 increase usage by nearly 50% bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that sales of its CyPath® Lung test for lung cancer increased more than 100% through the third quarter of 2026 compared to 2025, reflecting continued growth in clinical adoption of the Company’s noninvasive test for assessing the likelihood of lung cancer in high-risk individuals. The number of ordering physicians increased by 89% in

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Companies debut federal distribution collaboration to VA leadership, administrators and physicians at NAVREF 2026bioAffinity engages GO2 for Lung Cancer network to broaden outreach to veterans at riskbioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, is taking significant steps toward bringing its lung cancer test to the veterans who need it. This week, bioAffinity and its federal healthcare distribution partner AvMEDICAL, a Service-Disabled Veteran-Owned Small Business (SDVOSB), delivered the first joint exhibition of CyPath® Lung under their new distribution agreem

PRE 14A - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Presentations demonstrate beneficial role for CyPath Lung in veteran lung cancer care NAVREF 2026 focuses on innovative research to improve healthcare for veterans bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced it is presenting two posters highlighting its noninvasive lung cancer diagnostic, CyPath® Lung, in clinical practice and ongoing research evaluating the technology in veteran and military populations at the 2026 NAVREF Annual Conference, September 27-30, 2026, in Arlington, Virginia. The National Association of Veterans’ Research and

DENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The small-cap market is delivering a mix of catalysts, with the following companies in particular putting substantial new developments in front of investors: Aethlon Medical (NASDAQ:AEMD), NeOnc Technologies Holdings (NASDAQ:NTHI), bioAffinity Technologies (NASDAQ:BIAF), and Turbo Energy (NASDAQ:TURB). Aethlon Medical: Radical Reset Puts NOR-101 in the Spotlight Aethlon Medical (NASDAQ:AEMD) is attempting one of the most dramatic strategic resets in this group, announcing a definitive all-stock merger with privately held North Immunology alongside an oversubscribed private placement expected to generate approximately $180 million. If completed,

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian market Asia accounts for nearly two-thirds of lung cancer cases worldwide bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that the Hong Kong Intellectual Property Department has granted a patent for the Company’s proprietary platform technology for predicting the likelihood of lung cancer using flow cytometry and fluorescent markers to characterize cell populations in sputum. "The grant of this patent in Hong Kong and the 2025 patent we receive

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Across different corners of the market, the latest developments are putting investors’ attention back on tangible catalysts: NeOnc Technologies Holdings (NASDAQ:NTHI) is pairing fresh institutional capital with encouraging NEO100 clinical data; Opus Genetics (NASDAQ:IRD) is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; bioAffinity Technologies (NASDAQ:BIAF) removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; Tenon Medical (NASDAQ:TNON) eliminated roughly $5.16 million of convertible-note obligations ahead of maturity. NeOnc Raises $15